Changes in menopausal symptoms comparing oral estradiol versus transdermal estradiol

References

• El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. doi: 10.1097/GME.0000000000001424.
   PubMed Web of Science ®Google Scholar
• Chen R, Yu Q, Xu KH, et al. Survey on characteristics of menopause of Chinese women with the age 40–60 years at gynecological clinic from 14 hospitals. Chin J Obestet Gynecol. 2013;48(10):723–727.
   Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi: 10.3109/13697137.2015.1129166.
   PubMed Web of Science ®Google Scholar
• Beck KL, Anderson MC, Kirk JK. Transdermal estrogens in the changing landscape of hormone replacement therapy. Postgrad Med. 2017;129(6):632–636. doi: 10.1080/00325481.2017.1334507.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi: 10.1161/CIRCULATIONAHA.106.642280.
   PubMed Web of Science ®Google Scholar
• Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004;2(1):45. doi: 10.1186/1477-7525-2-45.
   PubMedGoogle Scholar
• Heinemann LAJ, Potthoff P, Schneider HPG. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003;1(1):28. doi: 10.1186/1477-7525-1-28.
   PubMedGoogle Scholar
• Wu H, Wen S, Hwang J, et al. Validation of the traditional Chinese version of the Menopausal Rating Scale with WHOQOL-BREF. Climacteric. 2015;18(5):750–756. doi: 10.3109/13697137.2015.1044513.
   PubMed Web of Science ®Google Scholar
• Wang XY, Yang HY, Nie GN, et al. Study on the reliability and validity of the Chinese Menopause Rating Scale (CMRS). Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29(9):882–886.
   PubMedGoogle Scholar
• MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric. 2001;4(1):58–74. doi: 10.1080/cmt.4.1.58.74.
   PubMedGoogle Scholar
• Gast GC, Pop VJ, Samsioe GN, et al. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease. Menopause. 2011;18(2):146–151. doi: 10.1097/gme.0b013e3181f464fb.
   PubMed Web of Science ®Google Scholar
• Szmuilowicz ED, Manson JE. Menopausal vasomotor symptoms and cardiovascular disease. Menopause. 2011;18(4):345–347. doi: 10.1097/gme.0b013e318209239a.
   PubMed Web of Science ®Google Scholar
• Nunez-Pizarro JL, Gonzalez-Luna A, Mezones-Holguin E, et al. Association between anxiety and severe quality-of-life impairment in postmenopausal women: analysis of a multicenter Latin American cross-sectional study. Menopause (New York, NY). 2017;24(6):645–652. doi: 10.1097/GME.0000000000000813.
   PubMed Web of Science ®Google Scholar
• Zöllner YF, Acquadro C, Schaefer M. Literature review of instruments to assess health-related quality of life during and after menopause. Qual Life Res. 2005;14(2):309–327. doi: 10.1007/s11136-004-0688-z.
   PubMed Web of Science ®Google Scholar
• Schneider HP, Heinemann LA, Rosemeier HP, et al. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric. 2000;3(1):59–64. doi: 10.3109/13697130009167600.
   PubMedGoogle Scholar
• Tao M, Shao H, Li C, et al. Correlation between the modified Kupperman Index and the Menopause Rating Scale in Chinese women. Patient Preference Adherence. 2013;7:223–229.
   PubMed Web of Science ®Google Scholar
• Schneider HP, Heinemann LA, Rosemeier HP, et al. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric. 2000;3(1):50–58. doi: 10.3109/13697130009167599.
   PubMedGoogle Scholar
• Miller VM, Taylor HS, Naftolin F, et al. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2021;24(2):139–145. doi: 10.1080/13697137.2020.1804545.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Anawalt B, Blackman MR, et al. The effect of endocrine disorders on lipids and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2023.
   Google Scholar
• Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol. 2002;90(8a):77i–84i. doi: 10.1016/s0002-9149(02)02637-1.
   PubMed Web of Science ®Google Scholar
• Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab. 2011;96(4):885–893. doi: 10.1210/jc.2010-2061.
   PubMed Web of Science ®Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril. 2001;75(5):898–915. doi: 10.1016/s0015-0282(01)01699-5.
   PubMed Web of Science ®Google Scholar
• Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt). 2012;21(2):161–169. doi: 10.1089/jwh.2011.2839.
   PubMed Web of Science ®Google Scholar
• Buster JE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother. 2010;11(9):1489–1499. doi: 10.1517/14656561003774098.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials. Breast Cancer Res Treat. 2012;132(1):275–285. doi: 10.1007/s10549-011-1848-9.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Karlamangla A, Huang MH, et al. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med. 2006;166(15):1578–1584. doi: 10.1001/archinte.166.15.1578.
   PubMedGoogle Scholar
• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause (New York, NY). 2017;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–260. doi: 10.7326/M14-0353.
   PubMed Web of Science ®Google Scholar
• Files JA, Miller VM, Cha SS, et al. Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study. J Womens Health (Larchmt). 2014;23(10):801–805. doi: 10.1089/jwh.2014.4871.
   PubMed Web of Science ®Google Scholar
• Kim S, Ko Y, Lee HJ, et al. Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies. Breast Cancer Res Treat. 2018;170(3):667–675. doi: 10.1007/s10549-018-4782-2.
   PubMed Web of Science ®Google Scholar
• Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet (London, England). 2019;394(10204):1159–1168.
   PubMed Web of Science ®Google Scholar
• Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128(1):144–156. doi: 10.1002/ijc.25314.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA. 2020;324(4):369–380. doi: 10.1001/jama.2020.9482.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Tamimi RM, Konings P, et al. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018;29(8):1771–1776. doi: 10.1093/annonc/mdy212.
   PubMed Web of Science ®Google Scholar
• Jin F, Tao M, Teng Y, et al. Knowledge and attitude towards menopause and hormone replacement therapy in Chinese women. Gynecol Obstet Invest. 2015;79(1):40–45. doi: 10.1159/000365172.
   PubMed Web of Science ®Google Scholar
• Chu K, Song Y, Chatooah ND, et al. The use and discontinuation of hormone replacement therapy in women in South China. Climacteric. 2018;21(1):47–52. doi: 10.1080/13697137.2017.1397622.
   PubMed Web of Science ®Google Scholar